Examkin

Question

Difficulty: HardPharmacologic Interventions

A 49-year-old premenopausal female is evaluated in the medical oncology clinic to discuss adjuvant therapy following a recent lumpectomy and sentinel lymph node biopsy. Pathology demonstrated a 1.5-cm, estrogen receptor-positive, progesterone receptor-positive, and HER2-negative invasive ductal carcinoma. Margins were negative, and no lymph nodes were involved. She completed adjuvant radiation therapy last week and is now scheduled to begin endocrine therapy. Her past medical history includes major depressive disorder, which has been well-controlled on paroxetine for the past 4 years. She currently reports no depressive symptoms but complains of moderate daily hot flashes. Vital signs and physical examination are unremarkable. The oncologist plans to start tamoxifen. Which of the following is the most appropriate recommendation regarding this patient's pharmacotherapy?

  1. Discontinue paroxetine and initiate venlafaxineAnswer
  2. B
    Discontinue paroxetine and initiate fluoxetine
  3. C
    Initiate anastrozole instead of tamoxifen and continue paroxetine
  4. D
    Continue paroxetine and initiate tamoxifen at a higher starting dose
  5. E
    Continue paroxetine, initiate tamoxifen, and monitor serum endoxifen levels

Answer

Discontinue paroxetine and initiate venlafaxine
The correct intervention is to discontinue paroxetine and initiate venlafaxine. Tamoxifen is a prodrug that is converted in the liver by the cytochrome P450 enzyme CYP2D6 into its highly active metabolite, endoxifen. Paroxetine is a potent inhibitor of CYP2D6. Concurrent administration of paroxetine and tamoxifen prevents this metabolic conversion, leading to subtherapeutic endoxifen levels and an increased risk of breast cancer recurrence. Therefore, paroxetine must be discontinued. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a weak inhibitor of CYP2D6 that does not significantly affect tamoxifen metabolism. Furthermore, venlafaxine is an excellent choice for this patient because it effectively treats both major depressive disorder and vasomotor symptoms (hot flashes), which the patient is currently experiencing.

Step-by-Step Solution

1
Identify the planned therapy and its mechanism of action.
The patient is scheduled to begin tamoxifen, a selective estrogen receptor modulator (SERM) that acts as a prodrug.
Understanding tamoxifen's metabolism is required to anticipate drug interactions.
2
Evaluate the patient's current medication list for pharmacokinetic interactions.
The patient is taking paroxetine. Tamoxifen requires activation by the hepatic enzyme CYP2D6 to its active metabolite, endoxifen. Paroxetine is a strong CYP2D6 inhibitor.
Concurrent use of strong CYP2D6 inhibitors prevents the formation of endoxifen, significantly reducing tamoxifen's efficacy and increasing the risk of breast cancer recurrence.
3
Determine the most appropriate pharmacologic adjustment.
Paroxetine must be discontinued. A safe alternative that does not inhibit CYP2D6, such as venlafaxine or escitalopram, should be initiated.
Venlafaxine will safely manage both the patient's major depressive disorder and her hot flashes without compromising the efficacy of tamoxifen.

Key Concept

Tamoxifen is a prodrug activated by CYP2D6; concurrent use of strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) reduces its efficacy and should be avoided by switching to safe alternatives like venlafaxine or escitalopram.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic